Peter Ordentlich - 01 Dec 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Scientific Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
01 Dec 2022
Net transactions value
-$466,638
Form type
4
Filing time
02 Dec 2022, 16:01:51 UTC
Previous filing
26 Aug 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $23,952 +3,772 +1423% $6.35 4,037 01 Dec 2022 Direct
transaction SNDX Common Stock Sale $94,343 -3,772 -93% $25.01 265 01 Dec 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $25,699 +4,028 +1520% $6.38 4,293 01 Dec 2022 Direct
transaction SNDX Common Stock Sale $100,746 -4,028 -94% $25.01 265 01 Dec 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $109,736 +17,200 +6491% $6.38 17,465 02 Dec 2022 Direct
transaction SNDX Common Stock Sale $430,936 -17,200 -98% $25.05 265 02 Dec 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -4,028 -100% $0.000000* 0 01 Dec 2022 Common Stock 4,028 $6.38 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -3,772 -100% $0.000000* 0 01 Dec 2022 Common Stock 3,772 $6.35 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -17,200 -100% $0.000000* 0 02 Dec 2022 Common Stock 17,200 $6.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $25.00 to $25.03.
F3 The sale prices ranged from $25.00 to $25.19.
F4 This option is fully vested.